Samsung BioLogics Co Ltd 207940
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 207940 is a good fit for your portfolio.
News
-
Samsung Biologics engages suppliers to advance global decarbonization targets
-
Samsung Biologics reports third quarter 2023 financial results
-
Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma's portfolio companies
-
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Trading Information
- Previous Close Price
- KRW 709,000.00
- Day Range
- KRW 705,000.00–716,000.00
- 52-Week Range
- KRW 668,000.00–845,000.00
- Bid/Ask
- KRW 708,000.00 / KRW 709,000.00
- Market Cap
- KRW 50.46 Tril
- Volume/Avg
- 53,728 / 52,908
Key Statistics
- Price/Earnings (Normalized)
- 51.88
- Price/Sales
- 13.80
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Samsung BioLogics Co Ltd engaged in development and manufacturing of bio-healthcare products.The Company works namely in Process Development, cGMP Manufacturing, Aseptic Fill and Finish.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 4,519
- Website
- https://www.samsungbiologics.com
Valuation
|
Metric
|
207940
|
|---|---|
Price/Earnings (Normalized) | 51.88 |
Price/Book Value | 5.29 |
Price/Sales | 13.80 |
Price/Cash Flow | 38.05 |
Price/Earnings
207940
Financial Strength
|
Metric
|
207940
|
|---|---|
Quick Ratio | 0.66 |
Current Ratio | 1.32 |
Interest Coverage | 13.36 |
Quick Ratio
207940
Profitability
|
Metric
|
207940
|
|---|---|
Return on Assets (Normalized) | 5.61% |
Return on Equity (Normalized) | 9.93% |
Return on Invested Capital (Normalized) | 7.84% |
Return on Assets
207940
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vjhx | $429.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nqxwpv | $92.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xjynq | $91.2 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Glxlh | $41.2 Bil | |
MRNA
| Moderna Inc | Llbc | $30.5 Bil | |
ARGX
| argenx SE ADR | Zzwn | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Yhq | $24.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bbpks | $22.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Phlmb | $17.9 Bil | |
INCY
| Incyte Corp | Jkwpsr | $12.4 Bil |